Skip to main content
TRUMY logo

Terumo Corporation (TRUMY) Stock Price & Analysis

Terumo Corporation (TRUMY) — price $16.20 (+3.05%), as of the Nov 19, 2026 trading session; market cap $23.9B.

Educational signal · not a buy or sell recommendation · How to read this

$16.20 +$0.48 (+3.05%) Market Cap $23.9B

Terumo Corporation · TRUMY · Healthcare · Medical - Devices

Terumo Corporation is a global medical technology company dedicated to the manufacturing and sale of a wide array of medical products and equipment, operating through three distinct business segments: Cardiac and Vascular…

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • STE · STERIS plc · 87 /100
  • PHG · Koninklijke Philips N.V. · 78 /100
  • DXCM · DexCom, Inc. · 93 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$16.20
Change on the day+3.05%
52-week range$12.08–$16.81
Market capitalisation$23.9B—
Price / earnings (trailing)33.04
Shares traded on the day5.9K
Beta (volatility vs the S&P 500)0.23

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $13, high $17, latest $16. $17 $13 high $17 Oct 17, 2025 Nov 19, 2026 · $16 $17Oct 17, 2025$16Oct 31, 2025$15Nov 14, 2025$15Nov 28, 2025$15Dec 12, 2025$15Dec 26, 2025$15Jan 9, 2026$14Jan 23, 2026$13Feb 6, 2026$13Feb 20, 2026$13Mar 6, 2026$13Mar 20, 2026$14Apr 2, 2026$14Apr 17, 2026$13May 1, 2026$13May 15, 2026$15May 29, 2026$14Jun 12, 2026$14Jun 26, 2026$14Jul 10, 2026$13Jul 24, 2026$16Aug 7, 2026$16Aug 21, 2026$16Sep 4, 2026$14Sep 18, 2026$14Oct 2, 2026$15Oct 16, 2026$15Oct 30, 2026$15Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Terumo (TRUMY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

1 lens, 1 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Neutral read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Moderate
Revenue Growth Moderate
Debt/Equity Moderate
ROE Neutral
Gross Margin Moderate

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Terumo (TRUMY), and what does it report?

Short answer

Terumo Corporation is a global medical technology company dedicated to the manufacturing and sale of a wide array of medical products and equipment, operating through three distinct business segments: Cardiac and Vascular… Healthcare / Medical Devices Headquarters: 2-44-1, Hatagaya, Tokyo, TY, 151-0072, JP. It employs 30,207 people and is led by Hikaru Samejima. In Q2 FY2027 it reported revenue of ¥312.47B and net income of -¥15.80B. The market values it at $23.9B.

2 · Latest results

What do the latest results show for Terumo (TRUMY)?

Short answer · as of

The most recent reported quarter, Q2 FY2027, carried revenue of ¥312.47B. Against analyst estimates the company has EPS beat 2 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2027¥312.47B-¥15.80B-¥10.71 (diluted)
Q1 FY2027¥311.81B¥70.43B¥47.73 (diluted)
Q4 FY2026¥305.84B¥26.85B¥17.58 (diluted)
Q3 FY2026¥301.98B¥33.24B¥21.96 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Terumo (TRUMY)?

Short answer · as of

The distress and quality screens read Altman Z 5.29 · Piotroski F 6. Trailing ratios: ROE 7.1% · ROA 5.1% · current ratio 2.87 · earnings yield 3.1% · free-cash-flow yield 5.3%.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
  • Rich valuation — a P/E of 33.04 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held TRUMY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported TRUMY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Terumo (TRUMY)?

Read these with our analysis →

Terumo Healthcare Stock: Key Questions Answered

Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.

What does Terumo’s Cardiac and Vascular business sell?

It supplies guidewires, catheters, stents, intravascular imaging, neurovascular devices, stroke-treatment tools, cardiopulmonary systems, and vascular graft products. Demand is linked to cardiovascular and cerebrovascular procedures rather than routine equipment replacement alone.

How does Terumo’s Blood and Cell Technologies business make money?

The business sells blood bags, collection and automated processing systems, pathogen-reduction tools, apheresis systems, and cell-expansion platforms. Its commercial exposure follows blood collection, component processing, therapeutic apheresis, and cell-management activity.

Why does Terumo manufacture prefillable syringes for pharmaceutical companies?

Prefillable syringes and needles place Terumo inside pharmaceutical drug-packaging programs as a contract manufacturer. That activity differs from selling devices directly for procedures because demand follows the packaging and delivery requirements of drugmakers.

What is the TRUMY stock price today?

The last price recorded for Terumo Corporation (TRUMY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 15 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • FAQ: What does Terumo’s Cardiac and Vascular business sell?: Business description
  • FAQ: How does Terumo’s Blood and Cell Technologies business make money?: Business description
  • FAQ: Why does Terumo manufacture prefillable syringes for pharmaceutical companies?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.